AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36087008 — intervention group
Group type: COMPARATOR
Intervention: IVMP alone (control group not explicitly mentioned)
Number of subjects: 9
Study 33043845 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative temporal bone CT showing a small facial recess
Number of subjects: 91
Study 33043845 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative temporal bone CT showing a prominent sigmoid sinus
Number of subjects: 91
Study 33043845 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MRI brain and internal auditory canal findings
Number of subjects: 91
Study 33043845 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CT findings
Number of subjects: 91
Study 32220153 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine, Quetiapine, Risperidone, Ziprasidone
Number of subjects: 1338
Study 32220153 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 1338
Study 32220153 — intervention group
Group type: EXPERIMENTAL
Intervention: SZ + AUD
Number of subjects: 1338
Study 35547000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar (32 mg)
Number of subjects: 81
Study 35547000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar (48 mg)
Number of subjects: 81
Study 35547000 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 81
Study 33198702 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 110
Study 33198702 — intervention group
Group type: COMPARATOR
Intervention: Supervised training
Number of subjects: 110
Study 33899090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-driven health and lifestyle modification programme
Number of subjects: 256
Study 33899090 — intervention group
Group type: COMPARATOR
Intervention: Standard care and general information about risk factor management (Control)
Number of subjects: 256
Study 32192799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4795
Study 32192799 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4795
Study 35933966 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution, high contrast MRI for neurovascular contact assessment
Number of subjects: 94
Study 35933966 — intervention group
Group type: COMPARATOR
Intervention: Control group (47 controls)
Number of subjects: 94
Study 33710299 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of the oral GABA reuptake inhibitor tiagabine
Number of subjects: 52
Study 33710299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 35981820 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy with conservative management
Number of subjects: 4480
Study 35981820 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy with invasive management
Number of subjects: 4480
Study 33616303 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic CT (sCT) software for general pelvis anatomy developed by Philips Healthcare.
Number of subjects: 147
Study 33616303 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic CT (sCT) software for general pelvis anatomy.
Number of subjects: 147
Study 32541132 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen (H2) therapy
Number of subjects: 58
Study 32541132 — intervention group
Group type: COMPARATOR
Intervention: Control group (no H2 therapy)
Number of subjects: 58
Study 32541132 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 + chemotherapy
Number of subjects: 58
Study 32541132 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 + targeted therapy
Number of subjects: 58
Study 32541132 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 + immunotherapy
Number of subjects: 58
Study 32541132 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy groups (H2 with chemotherapy, targeted therapy, or immunotherapy)
Number of subjects: 58
Study 35738852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine treatment
Number of subjects: 1012
Study 35738852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine treatment in patients with cardiac resynchronization therapy (CRT) ICDs
Number of subjects: 1012
Study 35738852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine treatment in patients with ICDs without CRT
Number of subjects: 1012
Study 35738852 — intervention group
Group type: COMPARATOR
Intervention: Concomitant AAD therapy
Number of subjects: 1012
Study 32698681 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Number of subjects: 157
Study 32698681 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Number of subjects: 157
Study 33177429 — intervention group
Group type: EXPERIMENTAL
Intervention: Various surgical treatments for tibial plateau fractures
Number of subjects: 2106
Study 33177429 — intervention group
Group type: COMPARATOR
Intervention: Perioperative antibiotic prophylaxis
Number of subjects: 2106
Study 35307131 — intervention group
Group type: EXPERIMENTAL
Intervention: HOB elevation to 30 degrees
Number of subjects: 307
Study 35307131 — intervention group
Group type: EXPERIMENTAL
Intervention: HOB elevation to 15 degrees
Number of subjects: 307
Study 35307131 — intervention group
Group type: COMPARATOR
Intervention: HOB 0 degree (control group)
Number of subjects: 307
Study 32327093 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (BMI <25 kg/m2)
Number of subjects: 2238
Study 32327093 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (25 kg/m2 ≤BMI <30 kg/m2)
Number of subjects: 2238
Study 32327093 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥30 kg/m2)
Number of subjects: 2238
Study 34016658 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enteral nutrition until extubation
Number of subjects: 0
Study 34016658 — intervention group
Group type: COMPARATOR
Intervention: 6-hour fasting prior to extubation
Number of subjects: 0
Study 32183390 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% O2
Number of subjects: 0
Study 32183390 — intervention group
Group type: COMPARATOR
Intervention: 20% O2
Number of subjects: 0
Study 35671862 — intervention group
Group type: EXPERIMENTAL
Intervention: Helminthostachys zeylanica (HZ) for 42 days
Number of subjects: 45
Study 35671862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) for 42 days
Number of subjects: 45
Study 33451253 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric loading program followed by stretching exercises combined with extracorporeal shockwave therapy (ESWT)
Number of subjects: 50
Study 33451253 — intervention group
Group type: COMPARATOR
Intervention: Sham ESWT
Number of subjects: 50
Study 32223566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic multiherbal medication administered daily for 1 month followed by 5 months of oral medication.
Number of subjects: 52
Study 35557490 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide/bortezomib/dexamethasone
Number of subjects: 700
Study 35557490 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration
Number of subjects: 700
Study 33091863 — intervention group
Group type: EXPERIMENTAL
Intervention: Total liver volume (T), left liver volume (L), right liver volume (R), caudate liver volume (C), spleen volume (S), L/T ratio, C/T ratio
Number of subjects: 165
Study 33091863 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudate liver volume (C), spleen volume (S), C/T ratio
Number of subjects: 165
Study 36129886 — intervention group
Group type: EXPERIMENTAL
Intervention: Jewelry-making sessions held twice a week for four weeks
Number of subjects: 62
Study 34474096 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment of LV end-diastolic volume index (EDVI) using traditional approach
Number of subjects: 120
Study 34474096 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment of LV end-diastolic volume index (EDVI) using recommended approach
Number of subjects: 120
Study 34474096 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment of aortic end-diastolic flow velocity (EDFV)
Number of subjects: 120
Study 34474096 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive/negative likelihood ratios for ruling in/ruling out severe AR using EDVI (traditional)
Number of subjects: 120
Study 34474096 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive/negative likelihood ratios for ruling in/ruling out severe AR using EDVI (recommended)
Number of subjects: 120
Study 34474096 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive/negative likelihood ratios for ruling in/ruling out severe AR using EDFV
Number of subjects: 120
Study 34474096 — intervention group
Group type: EXPERIMENTAL
Intervention: Using derived cut-off values instead of >2 SD
Number of subjects: 120
Study 34474096 — intervention group
Group type: EXPERIMENTAL
Intervention: Using EDFV ≤10 cm/s instead of ≤20 cm/s
Number of subjects: 120
Study 35544239 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuranolone
Number of subjects: 0
Study 35544239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34255246 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Number of subjects: 9594
Study 34255246 — intervention group
Group type: COMPARATOR
Intervention: Total Gastrectomy
Number of subjects: 9594
Study 34255246 — intervention group
Group type: COMPARATOR
Intervention: Total Gastrectomy (after matching)
Number of subjects: 9594
Study 34255246 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagectomy (after matching)
Number of subjects: 9594
Study 34255246 — intervention group
Group type: COMPARATOR
Intervention: Total Gastrectomy vs Esophagectomy (adjusted analyses)
Number of subjects: 9594
Study 33446284 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha2-adrenergic antagonist)
Number of subjects: 114
Study 33446284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 34047403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transversus thoracis muscle plane blocks (TP group)
Number of subjects: 60
Study 34047403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 60
Study 35202974 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus ramucirumab (arm A)
Number of subjects: 110
Study 35202974 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel plus ramucirumab (arm B)
Number of subjects: 110
Study 32835877 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid-mediated Photodynamic Therapy (5-ALA-PDT)
Number of subjects: 80
Study 33001138 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, 600 mg daily for 8 weeks
Number of subjects: 132
Study 33001138 — intervention group
Group type: COMPARATOR
Intervention: Placebo, size-matched, taken orally for 8 weeks
Number of subjects: 132
Study 33001138 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 132
Study 33001138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 35657073 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day course of levofloxacin
Number of subjects: 310
Study 35657073 — intervention group
Group type: COMPARATOR
Intervention: 7-day course of levofloxacin
Number of subjects: 310
Study 33969792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin-heparin-lock
Number of subjects: 25
Study 33969792 — intervention group
Group type: COMPARATOR
Intervention: Non-heparin, high-dose vancomycin-lock
Number of subjects: 25
Study 32729820 — intervention group
Group type: COMPARATOR
Intervention: JY09 6.0 mg
Number of subjects: 5
Study 32729820 — intervention group
Group type: COMPARATOR
Intervention: JY09 (various doses 0.3, 0.7, 1.5, 3.0, and 6.0 mg)
Number of subjects: 5
Study 32729820 — intervention group
Group type: COMPARATOR
Intervention: JY09
Number of subjects: 5
Study 35431250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) for 12 weeks
Number of subjects: 56
Study 35431250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 56
Study 34171938 — intervention group
Group type: EXPERIMENTAL
Intervention: AS201‐01 tablets (4 tablets, twice daily for 4 days)
Number of subjects: 30
Study 34171938 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (4 tablets, twice daily for 4 days)
Number of subjects: 30
Study 34266839 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCDEF bundle protocol
Number of subjects: 150
Study 34266839 — intervention group
Group type: COMPARATOR
Intervention: Non-protocolised standard care
Number of subjects: 150
Study 33074283 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid-focused plan
Number of subjects: 8010
Study 33074283 — intervention group
Group type: COMPARATOR
Intervention: Commercial managed care plan
Number of subjects: 8010
Study 33855879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve and tendon gliding exercises in addition to wrist splint use
Number of subjects: 80
Study 33855879 — intervention group
Group type: COMPARATOR
Intervention: Wrist splint use only
Number of subjects: 80
Study 32623839 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin 50 mg daily
Number of subjects: 0
Study 32623839 — intervention group
Group type: COMPARATOR
Intervention: metformin 1,000‐1,500 mg daily
Number of subjects: 0
Study 32447796 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-private life conflicts
Number of subjects: 3398
Study 32447796 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunities for development and behaviour of the direct line manager
Number of subjects: 3398
Study 36175904 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing lullaby for mother (B)
Number of subjects: 100
Study 36175904 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing lullaby for a mother while holding a photo of her own baby (C)
Number of subjects: 100
Study 36175904 — intervention group
Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 100
Study 35501887 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained community‐oriented resource persons (CORPs) conducting community‐based screening of BP, referral, diagnosis confirmation, initial treatment, monthly home‐based follow-up care, and health education.
Number of subjects: 200
Study 35501887 — intervention group
Group type: COMPARATOR
Intervention: Usual care (diagnosis, treatment and follow‐up care in hospital of a patient’s choice).
Number of subjects: 200
Study 34817082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 724
Study 34817082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 33958325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight-control/treat-to-target strategy (TC/T2T) with visits every 4 weeks and treatment intensification until achieving ASDAS <2.1
Number of subjects: 160
Study 33958325 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) with visits every 12 weeks and treatment at the rheumatologist's discretion
Number of subjects: 160
Study 32929684 — intervention group
Group type: EXPERIMENTAL
Intervention: Early shunt embolization (ESE)
Number of subjects: 67
Study 32929684 — intervention group
Group type: EXPERIMENTAL
Intervention: Late shunt embolization (LSE)
Number of subjects: 67
Study 32929684 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (Control)
Number of subjects: 67
Study 34743379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrison Protein Plus Multifibre®
Number of subjects: 35
Study 34743379 — intervention group
Group type: COMPARATOR
Intervention: Diason®
Number of subjects: 35
Study 34743379 — intervention group
Group type: COMPARATOR
Intervention: Glucerna Select®
Number of subjects: 35
Study 34521465 — intervention group
Group type: EXPERIMENTAL
Intervention: MED intervention (medication review by a pharmacist and geriatrician in the ED)
Number of subjects: 200
Study 34521465 — intervention group
Group type: EXPERIMENTAL
Intervention: MULTI‐NUT‐MED intervention (MED intervention + dietary counseling and individualized interventions)
Number of subjects: 200
Study 34521465 — intervention group
Group type: COMPARATOR
Intervention: eGFR equations
Number of subjects: 200
Study 35137699 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics (off-label use)
Number of subjects: 0
Study 35137699 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of antipsychotics after 4 months
Number of subjects: 0
Study 34325984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal breathing through a damp gauze for 10 minutes during vocal warm-up exercises
Number of subjects: 61
Study 34325984 — intervention group
Group type: COMPARATOR
Intervention: Vocal warm-up exercises without hydration procedures for 10 minutes
Number of subjects: 61
Study 34325984 — intervention group
Group type: COMPARATOR
Intervention: Talking using normal speaking voice for 10 minutes
Number of subjects: 61
Study 35014601 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT alone
Number of subjects: 44
Study 35014601 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (R-FMT)
Number of subjects: 44
Study 35014601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Metronidazole (CM-FMT)
Number of subjects: 44
Study 35014601 — intervention group
Group type: COMPARATOR
Intervention: Placebo FMT
Number of subjects: 44
Study 36198262 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible group (n=103)
Number of subjects: 207
Study 36198262 — intervention group
Group type: COMPARATOR
Intervention: Ineligible group (n=104)
Number of subjects: 207
Study 36198262 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible group
Number of subjects: 207
Study 33567589 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Replenishment Group 1 (1000 mL)
Number of subjects: 76
Study 33567589 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Replenishment Group 2 (500 mL)
Number of subjects: 76
Study 33567589 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Replenishment Group 3 (200 mL)
Number of subjects: 76
Study 33567589 — intervention group
Group type: COMPARATOR
Intervention: Non-Replenishment Group (NR)
Number of subjects: 76
Study 35082003 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 24
Study 35082003 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24
Study 33631326 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual Distress and Resources Questionnaire (SDRQ)
Number of subjects: 219
Study 33631326 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability of SDRQ
Number of subjects: 219
Study 36076107 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled vanilla essential oil (VEO)
Number of subjects: 142
Study 36076107 — intervention group
Group type: COMPARATOR
Intervention: Inhaled lavender essential oil (LEO)
Number of subjects: 142
Study 34737452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib plus fulvestrant
Number of subjects: 361
Study 34737452 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 361
Study 36151441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase before endovascular treatment
Number of subjects: 649
Study 36151441 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment only
Number of subjects: 649
Study 36326154 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA) with obturator nerve block (ONB) using plain Bupivacaine
Number of subjects: 72
Study 36326154 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA) with muscle relaxation
Number of subjects: 72
Study 32483851 — intervention group
Group type: EXPERIMENTAL
Intervention: unsupervised pelvic floor muscle training (PFMT)
Number of subjects: 73
Study 32483851 — intervention group
Group type: COMPARATOR
Intervention: lecture with no PFMT
Number of subjects: 73
Study 32729749 — intervention group
Group type: EXPERIMENTAL
Intervention: OrganOx metra
Number of subjects: 0
Study 32729749 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage (SCS)
Number of subjects: 0
Study 36481203 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 31
Study 36481203 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 31
Study 34043280 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 98
Study 32539893 — intervention group
Group type: COMPARATOR
Intervention: CS200 (200 mg CS per kg feed)
Number of subjects: 320
Study 32539893 — intervention group
Group type: COMPARATOR
Intervention: CS100 (100 mg CS per kg feed)
Number of subjects: 320
Study 35014145 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Therapy (metformin/exenatide/pioglitazone)
Number of subjects: 68
Study 35014145 — intervention group
Group type: COMPARATOR
Intervention: Conventional Therapy (metformin → glipizide → glargine insulin)
Number of subjects: 68
Study 35014145 — intervention group
Group type: COMPARATOR
Intervention: Conventional Therapy
Number of subjects: 68
Study 35014145 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Therapy
Number of subjects: 68
Study 33967075 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation therapy (VRT)
Number of subjects: 24
Study 33967075 — intervention group
Group type: EXPERIMENTAL
Intervention: Noisy galvanic vestibular stimulation (nGVS)
Number of subjects: 24
Study 33967075 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 35026362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided suprainguinal fascia iliaca block (SFIB) + sham AQLB
Number of subjects: 100
Study 35026362 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided anterior quadratus lumborum block (AQLB) + sham SFIB
Number of subjects: 100
Study 36401070 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CGF
Number of subjects: 16
Study 36401070 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + A-PRF
Number of subjects: 16
Study 36401070 — intervention group
Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 16
Study 34495065 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency (group H)
Number of subjects: 64
Study 34495065 — intervention group
Group type: COMPARATOR
Intervention: Standard-voltage pulsed radiofrequency (group S)
Number of subjects: 64
Study 32394855 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag (doses: 1200‐1600 µg b.i.d., 600‐1000 µg b.i.d., 200‐400 µg b.i.d.)
Number of subjects: 26
Study 32394855 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 26